J. Safra Sarasin Holding AG Takes Position in Annexon, Inc. (NASDAQ:ANNX)

J. Safra Sarasin Holding AG bought a new position in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 155,744 shares of the company's stock, valued at approximately $799,000. J. Safra Sarasin Holding AG owned approximately 0.15% of Annexon as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ANNX. Tower Research Capital LLC TRC lifted its stake in shares of Annexon by 345.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 24,892 shares of the company's stock valued at $128,000 after buying an additional 19,301 shares in the last quarter. MetLife Investment Management LLC lifted its position in Annexon by 17.7% in the 4th quarter. MetLife Investment Management LLC now owns 64,967 shares of the company's stock valued at $333,000 after acquiring an additional 9,755 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Annexon by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,360,076 shares of the company's stock valued at $6,977,000 after purchasing an additional 231,034 shares during the last quarter. CANADA LIFE ASSURANCE Co bought a new stake in Annexon during the 4th quarter worth approximately $77,000. Finally, Walleye Capital LLC raised its stake in shares of Annexon by 99.7% in the fourth quarter. Walleye Capital LLC now owns 656,332 shares of the company's stock worth $3,367,000 after purchasing an additional 327,634 shares during the last quarter.

Annexon Stock Up 4.5 %

Shares of ANNX opened at $1.84 on Thursday. The business's 50-day moving average price is $2.21 and its 200-day moving average price is $4.32. Annexon, Inc. has a twelve month low of $1.29 and a twelve month high of $7.85. The stock has a market cap of $201.87 million, a PE ratio of -1.75 and a beta of 1.24.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a "buy" rating and issued a $16.00 price target on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.